Alembic Pharmaceuticals Limited Investor Presentation March 2014 BSE: Symbol: ALEMPHARM Code: 533573 NSE: Symbol: APLLTD ISIN: INE901L01018 www.alembic-india.com
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited, to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment and governmental laws and regulations affecting domestic and foreign operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited, to inability to build production capacity to meet demand, unavailability of raw materials and failure to gain market acceptance.
The Alembic Journey 2003 St a t e - of - t he - a r t 2001 F or mul a t i ons f a ci l i t y f or St a r t s Re gul a t or y ma nuf a ct ur i ng 1972 Ma r k e t s of " Al t hr oci n" -a Ce pha l os por i n C 1971 br a nd of Er y t hr omy ci n Er y t hr omy ci n l a unche d 1961 ma nuf a ct ur e d f or t he f i r s t La l Ba ha dur t i me i n I ndi a 1940 Sha s t r i , t he t he n St a r t e d Pr i me mi ni s t e r ma nuf a ct ur i ng 1907 i na ugur a t e s t he cough s y r up, Pe ni ci l l i n pl a nt St a r t e d v i t a mi ns , t oni cs ma nuf a ct ur i ng a nd s cul pt ur e t i nct ur e s a nd dr ugs a l cohol a t Va doda r a
The Alembic Journey 2014 -Pa r a I V f i l e d 2011 -Cumul a t i v e l y 61 ANDAs f i l e d, -ANVI SA ( 32 ANDA/ NDA a ppr ov a l s 2010 a ppr ov e d) -Aggr e s s i v e a nd 66 DMF s -Az i t hr a ls a l e s ANDAs a nd 2009 Re a ch I NR DMF s f i l i ng 1000 mi l l i on Addr e s s e d ma r k 2007 chr oni c t he r a pi e s -De me r ge r AL - APL t hr ough Acqui s i t i on of mul t i pl e 2006 Non- Oncol ogy ma r k e t i ng Bus i ne s s of di v i s i ons US F DA M/ s Da bur a ppr ov a l s f or 2004 Pha r ma Lt d. API a nd St a t e - of - t he - a r t F or mul a t i on Re s e a r ch Pl a nt s Ce nt r e e s t a bl i s he d i n Va doda r a
Strategic Advantage Alembic Research Centre is Well-developed the first in India to be Infrastructure facility - Information Security Certified 4 US FDA approved plants High-end quality / Highly talented pool of RA structure 300 Research Scientists Manufacturing excellence R&D / F&D / Captive with optimal cost benefits Bio-equivalence facility Therapy focused marketing Therapy focused marketing Strong partnership Long term relationship with through 15 marketing arms through over 4,000 field force and alliance on PAN India basis covering over 1.5 lacs doctors in Generic space API customers
Alembic Research Centre State-of-the-art Analytical & IPR infrastructure R&D F ACI LI TY F&D CAPABI LI TI ES BI O EQUI VALENCE CENTRE R&D Centre has been Expertise in Drug Deliveries State-of-the-art 90-bedded new recognized by DSIR, and Niche Formulations Bio Centre Govt. of India Well-defined Processes 100 Bio Pilot Studies High-end R&D Equipment - and Quality Systems NMR XRD, TGA, DSC, LCMS Capabilities in Solid Oral, 50 Pivotal Studies World-class Infrastructure Liquid Oral Products
Research Capabilities FORMULATIONS API 61 66 60 ANDA Filing ANDAs filed DMFs filed ANDAs filed DMFs filed with DMFs Filing DMFs Filing 32 ANDA / NDA approvals 61 61 66 66 57 57 60 60 54 54 44 44 45 45 37 37 32 32 25 25 26 26 18 18 26 18 13 12 13 9 7 7 6 6 6 4 Up to Up to 2009-10 2009-10 2010-11 2010-11 2011-12 2011-12 2012-13 2012-13 2013-14 2013-14 Up to Up to 2009-10 2009-10 2010-11 2010-11 2011-12 2011-12 2012-13 2012-13 2013-14 2013-14 2008-09 2008-09 2008-09 2008-09
Manufacturing Infrastructure For m ul at i ons -Gener i cs API Br anded For m ul at i ons ( Re gul a t or y Ma r k e t s ) USFDA, MCC, MHRA, Formulations plant at USFDA, EDQM, TGA, WHO ANVISA, TPD approved Baddi, Himachal Pradesh approved API facility at formulations facility at Panelav Panelav (2 units) and at Karkhadi (1 unit) Current annual production capacity of plus 5 billion tablets/capsules
Manufacturing Infrastructure Certifications
Effective Marketing PAN India Marketing and Distribution Network OSTEOFIT ZENOVI Orthopedics Gynecology SPECIA Cardiology SUMMIT EYECARE Diabetes INTENSA Cardiology ENTERON Ophthalmology Diabetes Critical Care Gastroenterology Urology GASTRON ALCARE CORAZON Gastroenterology Gynecology RESPIRATORY Cardiology High End Diabetes Respiratory SPECIALITY MARKETING MAXIS CORIUM DIVISION Rural Dermatology Focused MEGACARE PHARMA General Acute General Acute Division Division
Major Product Portfolio Top Therapatic Ranking * Other Therapatic Products Area Products Area Rekool Gastroenterology Azithral 35 Anti Infective Zeet/Bro-Zeet Cough & Cold Althrocin Anti Infective 63 Tellzy Cardiology Wikoryl 152 Respiratory Gestofit Gynecology Sharkoferrol Tonic Roxid 164 Anti Infective Tetan Cardiology 284 Gestofit Gynecology Livfit Hepaprotectives Zofix Anti Infective Ulgel Antacid and Anti Flatulant Glisen Anti Diabetic Ovigyn Gynecology * Source: ORG March, 2014
Growth Drivers Branded Formulations Enhanced focus on existing branded business Through effective pan-India distribution Expected network and therapy based marketing annual growth and by pushing ahead acute and chronic segments like anti-infectives and cough 15-18% & cold medications Launch 20-25 new products Launch of new products to boost sales momentum and brand build up Enter into new therapeutic segment Corazon for Cardio and Alembic Respiratory for High end Respiratory launches in early FY 2014-15
Growth Drivers International Generics Superior cost efficiency Position Alembic as a cost efficient dependable quality manufacturer Expanded annual production capacity Annual production enhanced from 2.6 billion tablets/capsules to 5 billion tablets/capsules. ANDA filings and approvals for off-patent drugs Over the next five years, products that currently generate more than USD 142 billion In sales are expected to go off-patent. Alembic can tap these opportunities by launching new generic products at appropriate times.
Financial Highlights – Quarterly Consolidated Q IV - FY 13-14 INR million Sales Q IV / 13-14 Q IV / 12-13 Business Share '14 Growth % Formulation India Branded 1,995 1,753 43% 14% 286 298 6% -4% India Generics International Branded 176 153 4% 15% International Generics 1,367 76% 776 29% API 809 787 18% 3% Export Incentive 19 17 23% 4,652 3,784 100% Grand Total 2,453 2,338 53% Total Domestic 5% 2,199 47% 52% Total Export 1,446
Financial Highlights – Quarterly Result Highlight (Consolidated) Q IV - FY 13-14 INR million Particulars Q IV / 13-14 Growth % Q IV / 12-13 EBDITA (Before R&D) 1,225 882 39% 39% EBDITA (Post R&D) 913 656 EBDITA % 17.3% 19.6% PBT 808 552 46% PAT 40% 613 437
Financial Highlights – 2013-14 Consolidated FY 2013-14 INR million Sales 2013-14 2012-13 Business Share '14 Growth % Formulation India Branded 8,506 7,484 46% 14% 1,207 1,262 6% -4% India Generics International Branded 736 558 4% 32% International Generics 4,684 99% 2,358 25% API 3,388 3,505 18% -3% Export Incentive 163 93 22% 18,684 15,260 100% Grand Total 10,411 9,971 56% Total Domestic 4% 8,273 44% 56% Total Export 5,289
Financial Highlights – 2013-14 Result Highlight (Consolidated) FY 2013-14 INR million Particulars Growth % 2013-14 2012-13 EBDITA (Before R&D) 4,741 45% 3,263 3,577 2,520 EBDITA (Post R&D) 42% EBDITA % 16.5% 19.2% PBT 3,106 2,064 51% PAT 43% 2,355 1,653
Revenue Overview Sales Composition FY 13-14 API Export Export Incentive 1% 15% API Domestic 3% India Branded Formulations International Generics 46% 25% International Branded Formulation India Generics 4% 6%
Recommend
More recommend
